What Is the First-Line Treatment for Vulvar Lichen Sclerosus?
Vulvar lichen sclerosus is a chronic inflammatory skin condition affecting the vulvar region. This page outlines the first-line clinical approach and the outcome measure used to confirm a treatment response.
Treatment Target
The primary goal is resolution of lichen sclerosus. Response to treatment is formally assessed at 3 months after initiating therapy.
First-Line Approach
Management centres on topical therapy applied directly to the affected vulvar skin. The complete regimen — including the specific agents, potency selection, and application schedule — is contained in the full protocol.
References
DOI: 10.1111/jdv.18102
- Ultra-potent or potent topical steroids e.g. clobetasol proprionate or mometasone furoate are first line recommendations for genital LS (GRADE 1, A).
- Various regimens are used; one of the most common being daily use of potent to ultra-potent topical steroids (usually once daily) for three months.
- Twice daily application may occasionally be of additional benefit in resistant LS.
- After 3 months to assess response to treatment.